Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Maria Markosyan Karapetyan

Internal Medicine Brighton, MI Medical Doctor

NPI 1184152282 CMS profile 8800295

10415 Grand River Rd Ste 100, Brighton, MI 48116

Open in the dashboard

General payments

$7,751

454 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maria Markosyan Karapetyan of Brighton, MI is reported in the CMS Open Payments database as having received $7,751 across 454 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,847 96
2024 General $1,851 114
2023 General $1,566 95
2022 General $1,749 110
2021 General $717 38
2020 General $22 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maria Markosyan Karapetyan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Maria Markosyan Karapetyan were reported at $1,847. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Maria Markosyan Karapetyan Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $22 $119 $33–$402 $114
2021 $717 $135 $37–$521 $132
2022 $1,749 $141 $42–$496 $149
2023 $1,566 $149 $45–$519 $160
2024 $1,851 $154 $47–$537 $164
2025 $1,847 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Novo Nordisk Inc $1,371 94 payments
  2. AbbVie, Inc. $1,067 58 payments
  3. AstraZeneca Pharmaceuticals LP $998 53 payments
  4. Lilly USA, LLC $805 55 payments
  5. Pfizer Inc. $615 35 payments
  6. GlaxoSmithKline, LLC. $328 21 payments
  7. Amgen Inc. $311 19 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $273 13 payments
  9. Exact Sciences Corporation $207 10 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $201 12 payments
  11. Other $1,576 84 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $7,751 454 payments
Products named General payments · program years 2020–2025
  1. UBRELVY $554 29 payments
  2. QULIPTA $554 29 payments
  3. FARXIGA $472 20 payments
  4. NURTEC ODT Pain $460 28 payments
  5. MOUNJARO $459 32 payments
  6. BREZTRI $443 19 payments
  7. Wegovy $415 26 payments
  8. RYBELSUS $349 23 payments
  9. Ozempic $346 23 payments
  10. NURTEC ODT Primary Care $317 13 payments
  11. Other $5,901 341 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

416

Median for Internal Medicine: 777

Drug cost

$147,513

Median for Internal Medicine: $73,373

Branded share of claims

16.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aralast Np Alpha-1-Proteinase Inhibitor Brand 11 $99,584
Ozempic Semaglutide Brand 21 $29,241
Mounjaro Tirzepatide Brand 11 $15,417
Albuterol Sulfate Hfa Albuterol Sulfate Brand 24 $841
Atorvastatin Calcium Generic 39 $467
Levothyroxine Sodium Generic 27 $315
Pravastatin Sodium Generic 13 $242
Amlodipine Besylate Generic 46 $231
Lisinopril Generic 22 $183
Losartan Potassium Generic 11 $159

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$55,332

Of which drugs: $58

Medicare patients

160

Average age 74

Services billed

3,172

98 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Ischemic heart disease 41%
Diabetes 36%
Chronic kidney disease 32%
Heart failure 31%
Atrial fibrillation 27%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $146
$146 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $141
$141 — —
MOUNJARO
  • Lilly USA, LLC $132
$132 11 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $124
$124 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $107
$107 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

454 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record